{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:56:25Z","timestamp":1792652185431,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjpad.2026.100489","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:47:16Z","timestamp":1769215636000},"page":"100489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lecanemab over a two-year duration: Key insights from a regional specialty medical center"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1526-4063","authenticated-orcid":false,"given":"Lisa B.E.","family":"Shields","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8543-4353","authenticated-orcid":false,"given":"Hannah S.","family":"Hust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3401-911X","authenticated-orcid":false,"given":"Gregory E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6610-6355","authenticated-orcid":false,"given":"Theresa","family":"Kluthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7607-9728","authenticated-orcid":false,"given":"Rachel N.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Thaliath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7866-7081","authenticated-orcid":false,"given":"Brandon C.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie W.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica F.","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whoy Y.","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall M.","family":"Wasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish S.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth G.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2026.100489_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100489_bib0003","author":"Stewart"},{"key":"10.1016\/j.tjpad.2026.100489_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2026.100489_bib0005","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1177\/13872877251331640","article-title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: a systematic review of clinical evidence","volume":"105","author":"Ashmawy","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100489_bib0006","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100489_bib0007","doi-asserted-by":"crossref","first-page":"e3592","DOI":"10.1002\/brb3.3592","article-title":"Use of lecanemab for the treatment of Alzheimer's disease: a systematic review","volume":"14","author":"Hossain","year":"2024","journal-title":"Brain Behav"},{"key":"10.1016\/j.tjpad.2026.100489_bib0008","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100489_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1169499","article-title":"Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meat-analysis of randomized clinical trials","volume":"15","author":"Qiao","year":"2023","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.tjpad.2026.100489_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100489_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1559447","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab","volume":"16","author":"Yan","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tjpad.2026.100489_bib0012","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2022","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.tjpad.2026.100489_bib0013","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.14283\/jpad.2024.159","article-title":"Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center","volume":"11","author":"Shields","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2026.100489_bib0015","doi-asserted-by":"crossref","DOI":"10.1148\/rg.230009","article-title":"Amyloid-related imaging abnormalities in Alzheimer disease treated with anti-amyloid-beta therapy","volume":"43","author":"Agarwal","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.tjpad.2026.100489_bib0016","doi-asserted-by":"crossref","first-page":"E19","DOI":"10.3174\/ajnr.A7586","article-title":"Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice","volume":"43","author":"Cogswell","year":"2022","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.tjpad.2026.100489_bib0017","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13195-025-01763-1","article-title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","volume":"17","author":"Bregman","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100489_bib0018","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","article-title":"Lecanemab treatment in a specialty memory clinic","volume":"82","author":"Paczynski","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2026.100489_bib0020","article-title":"Characterizing clinician communication with patients about lecanemab: a qualitative study of clinicians across seven academic medical centers","volume":"11","author":"Parks","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100489_bib0021","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/13872877251329519","article-title":"A qualitative study of people with Alzheimer's disease in a memory clinic considering lecanemab treatment","volume":"105","author":"Parks","year":"2025","journal-title":"J Alzheimers Dis"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:39:00Z","timestamp":1773261540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2274580726000130"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100489","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lecanemab over a two-year duration: Key insights from a regional specialty medical center","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100489"}}